Lenvatinib - Eisai Co Ltd

Drug Profile

Lenvatinib - Eisai Co Ltd

Alternative Names: E-7080; ER-203492-00; Kisplyx; Lenvatinib mesylate; Lenvima

Latest Information Update: 06 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eisai Co Ltd
  • Developer Eisai Co Ltd; National University Hospital (Singapore); SFJ Pharmaceuticals
  • Class Amides; Antineoplastics; Chlorobenzenes; Cyclopropanes; Phenyl ethers; Quinolines; Small molecules; Urea compounds
  • Mechanism of Action Platelet derived growth factor alpha receptor antagonists; Proto oncogene protein c ret inhibitors; Proto oncogene protein c-kit inhibitors; Type 1 fibroblast growth factor receptor antagonists; Type 3 fibroblast growth factor receptor antagonists; Type 4 fibroblast growth factor receptor antagonists; Type-2 fibroblast growth factor receptor antagonists; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Thyroid cancer; Hepatocellular carcinoma; Malignant melanoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Renal cell carcinoma; Thyroid cancer
  • Preregistration Hepatocellular carcinoma
  • Phase II Biliary cancer; Endometrial cancer; Malignant melanoma; Non-small cell lung cancer; Thymoma
  • Phase I/II Breast cancer; Solid tumours
  • Phase I Ovarian cancer
  • No development reported Cancer; Lymphoma
  • Discontinued Glioma

Most Recent Events

  • 06 Dec 2017 Preregistration for Hepatocellular carcinoma (First-line therapy, Inoperable/Unresectable) in Taiwan (PO)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Cancer(In volunteers) in USA (PO, Suspension)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Lymphoma(Second-line therapy or greater) in Netherlands (PO, Tablet)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top